BioScience

Arsenal Biosciences, Inc. (ArsenalBio), a pioneering force in programmable cell therapy, has announced the successful closure of an oversubscribed $325 million Series C financing round. This significant funding boost reflects a growing confidence in ArsenalBio’s innovative approach to advanced CAR T-cell therapies targeting solid tumors. The Series C round attracted a host of new investors,…

ZBiotics, a trailblazer in the realm of genetically engineered probiotics, has successfully concluded its $12 million Series A funding round. The investment, led by Spring Tide Capital and supported by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures, marks a significant milestone for the company. The funds are set to fuel ZBiotics‘ plans…

Shinobi Therapeutics, a trailblazer in immune evasive iPS cell therapies, has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). This significant grant will accelerate the development of Shinobi’s pioneering iPS-T cell therapy, aimed at treating GPC3+ solid tumors. Dr. Yasumichi Hitoshi, Chief of…

Jade Biosciences, a biotechnology innovator focused on autoimmune diseases, has announced the successful closing of an $80 million financing round. Led by Fairmount and Venrock Healthcare Capital Partners, with additional contributions from Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP, this investment will drive the development of Jade’s cutting-edge therapies…

LTZ Therapeutics, an emerging leader in immunotherapy, has successfully completed a $20 million Series A financing round. This round, spearheaded by new investor Lapam Capital and including significant contributions from GL Ventures, K2 Venture Partners, and Shunwei Capital, brings LTZ’s total funding to approximately $50 million since its inception in 2022. The new capital will…